EP1718145A4 - Remedes conjugues de therapie et diagnostic du cancer - Google Patents

Remedes conjugues de therapie et diagnostic du cancer

Info

Publication number
EP1718145A4
EP1718145A4 EP05703160A EP05703160A EP1718145A4 EP 1718145 A4 EP1718145 A4 EP 1718145A4 EP 05703160 A EP05703160 A EP 05703160A EP 05703160 A EP05703160 A EP 05703160A EP 1718145 A4 EP1718145 A4 EP 1718145A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
diagnosis
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05703160A
Other languages
German (de)
English (en)
Other versions
EP1718145A2 (fr
Inventor
Stela Gengrinovitch
Esther Izakovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosight Ltd
Original Assignee
Biosight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosight Ltd filed Critical Biosight Ltd
Priority to EP15200535.1A priority Critical patent/EP3075247B1/fr
Publication of EP1718145A2 publication Critical patent/EP1718145A2/fr
Publication of EP1718145A4 publication Critical patent/EP1718145A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP05703160A 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer Withdrawn EP1718145A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15200535.1A EP3075247B1 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54033404P 2004-02-02 2004-02-02
PCT/IL2005/000117 WO2005072061A2 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15200535.1A Division EP3075247B1 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer

Publications (2)

Publication Number Publication Date
EP1718145A2 EP1718145A2 (fr) 2006-11-08
EP1718145A4 true EP1718145A4 (fr) 2012-03-07

Family

ID=34826214

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15200535.1A Active EP3075247B1 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer
EP05703160A Withdrawn EP1718145A4 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15200535.1A Active EP3075247B1 (fr) 2004-02-02 2005-02-02 Remedes conjugues de therapie et diagnostic du cancer

Country Status (3)

Country Link
US (2) US7989188B2 (fr)
EP (2) EP3075247B1 (fr)
WO (1) WO2005072061A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3075247B1 (fr) * 2004-02-02 2022-10-12 BioSight Ltd. Remedes conjugues de therapie et diagnostic du cancer
EP3530290A1 (fr) * 2005-05-05 2019-08-28 GlaxoSmithKline Intellectual Property Development Limited Conjugués d'un ester d'aminoacide alpha et d'un médicament hydrolysables par la carboxylestérase
CA2679700A1 (fr) * 2007-03-02 2008-09-12 Talia Miron Derives de mercaptopurine utilises en tant qu'agents anticancereux
KR100807358B1 (ko) * 2007-04-18 2008-02-28 (주)나노하이브리드 암조직 선택성과 생분해성을 갖는 고리형 삼합체포스파젠-백금(ｉｉ) 착물 컨쥬게이트 항암제 및 그 제조방법
WO2009048780A1 (fr) * 2007-10-08 2009-04-16 The University Of Kentucky Research Foundation Conjugués polymère-chélateur de métaux et leurs utilisations
WO2009106844A1 (fr) 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Inhibiteurs de la p38 map kinase
WO2009140186A1 (fr) * 2008-05-14 2009-11-19 Centocor Ortho Biotech Inc. Procédé de préparation de dérivés de peptides
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US20110054019A1 (en) * 2009-09-01 2011-03-03 Pedro Anastacio Serrano-Ojeda Cancer Starvation Therapy
US10292956B2 (en) * 2009-09-01 2019-05-21 Serbig Pharmaceutics Corp. Cancer starvation therapy
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
CN103936922B (zh) * 2014-04-11 2016-06-29 西北师范大学 具有抗肿瘤活性的6-巯基嘌呤共聚物及其制备方法
JP6817956B2 (ja) 2015-11-18 2021-01-20 日本化薬株式会社 新規なグルタミン酸誘導体とブロック共重合体を含有する組成物及びその用途
US11241427B2 (en) * 2015-11-29 2022-02-08 Kcl Therapeutics, Inc. Small molecule modulators of NR2F6 activity
CN108431017B (zh) * 2015-12-03 2021-12-21 拜欧赛特有限公司 用于癌症疗法的缀合物的盐
BR112018011177A2 (pt) * 2015-12-03 2018-11-21 Biosight Ltd conjugados de citarabina para terapia de câncer
WO2017094011A1 (fr) * 2015-12-03 2017-06-08 Biosight Ltd. Sels de conjugués en cancéro-thérapie
BR112019011033A2 (pt) * 2016-11-30 2019-10-15 Tyme Inc composição, método para reduzir a proliferação celular em um indivíduo, método para tratar câncer em um indivíduo e kit
CA3069558A1 (fr) * 2017-07-09 2019-01-17 Biosight Ltd. Polytherapie anticancereuse
CA3076193A1 (fr) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC Procedes et compositions pour inhiber les symptomes associes au sevrage des opioides
CA3091027A1 (fr) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Conjugues de medicaments a petites molecules de monophosphate de gemcitabine
WO2020014153A1 (fr) * 2018-07-09 2020-01-16 The Regents Of The University Of California Sondes fluorescentes redox-labiles et leurs procédés d'immobilisation sur une surface pour la détection de métabolites
EP3836971A4 (fr) * 2018-08-13 2022-06-22 Flagship Pioneering Innovations V, Inc. Conjugués et leurs procédés d'utilisation
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
CN112010811B (zh) * 2019-05-30 2022-04-22 首都医科大学 茶氨酸与苯丙氨酸共同修饰的5-氟尿嘧啶,其合成,活性和应用
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
US3041335A (en) 1959-04-21 1962-06-26 Hoffmann La Roche Mercury salts of nitrogen heterocyclics and preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348522A (en) 1980-01-23 1982-09-07 Starks Associates, Inc. N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
CA1305695C (fr) 1986-08-22 1992-07-28 Eit Drent Compositions de catalyseurs et procede pour la copolymerisation olefine-co
EP0329184A3 (fr) 1988-02-19 1990-05-23 Neorx Corporation Antimères et conjugaison antimère
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SI0769967T1 (sl) 1994-08-19 2008-06-30 Wallone Region Konjugati vsebujoäśi protitumorna sredstva in njihova uporaba
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
AU773420B2 (en) 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
US6605638B1 (en) 2000-12-20 2003-08-12 D-Pharm Limited Use of branched chain fatty acids and derivatives thereof for inhibition of P-glycoprotein
PL207834B1 (pl) * 2001-07-10 2011-02-28 Ge Healthcare As Związki na bazie peptydów, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
EP3075247B1 (fr) * 2004-02-02 2022-10-12 BioSight Ltd. Remedes conjugues de therapie et diagnostic du cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LEE H ET AL: "SYNTHESES OF DRUG-MACROMOLECULE CONJUGATES: CONJUGATIONS OF 5-FLUOROURACIL TO HUMAN SERUM ALBUMIN AND POLY-L-LYSINE", YAGHAG HOEJI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF KOREA, SEOUL, KR, vol. 33, no. 5, 1 January 1989 (1989-01-01), pages 267 - 272, XP002062904, ISSN: 0513-4234 *
LI C: "POLY(L-GLUTAMIC ACID)-ANTICANCER DRUG CONJUGATES", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 5, 1 January 2002 (2002-01-01), pages 695 - 713, XP001199485, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00045-5 *
MANFREDINI S ET AL: "Peptide T-araC conjugates: solid-phase synthesis and biological activity of N4-(acylpeptidyl)-araC", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 8, no. 3, 1 March 2000 (2000-03-01), pages 539 - 547, XP002601972, ISSN: 0968-0896 *
MASAYUKI YOKOYAMA: "Characterization and Anticancer Activity of the Micelle-forming Polymeric Anticancer Drug Adriamycin-conjugated Poly(ethylene glycol)-Poly(aspartic acid) Block Copolymer", CANCER RES, 1 January 1990 (1990-01-01), pages 1693 - 1700, XP055017571, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/50/6/1693.full.pdf> [retrieved on 20120125] *
MOCHIZUKI E ET AL: "Synthesis of poly-L-glutamates containing 5-substituted uracil moieties.", NUCLEIC ACIDS SYMPOSIUM SERIES 1985 LNKD- PUBMED:2418418, no. 16, 1985, pages 121 - 124, XP008147954, ISSN: 0261-3166 *
YAN GUO-PING ET AL: "Study on the anticancer drug 5-fluorouracil-conjugated polyaspartamide containing hepatocyte-targeting group", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, SAGE PUBLICATIONS, GB, vol. 16, no. 4, 1 July 2001 (2001-07-01), pages 277 - 293, XP008147800, ISSN: 0883-9115, DOI: 10.1106/M4LK-LWJQ-34CL-LR85 *

Also Published As

Publication number Publication date
EP3075247B1 (fr) 2022-10-12
WO2005072061A3 (fr) 2006-08-24
US8993278B2 (en) 2015-03-31
EP3075247A1 (fr) 2016-10-05
EP1718145A2 (fr) 2006-11-08
US20110275590A1 (en) 2011-11-10
WO2005072061A2 (fr) 2005-08-11
US7989188B2 (en) 2011-08-02
US20070072800A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
EP1718145A4 (fr) Remedes conjugues de therapie et diagnostic du cancer
EP1720575A4 (fr) Conjugues therapeutiques et diagnostiques utilisables avec des anticorps multispecifiques
EP1781689A4 (fr) Conjugues et utilisations therapeutiques correspondantes
EP1967209A4 (fr) Agent thérapeutique pour le cancer de la prostate
IL186662A0 (en) Combination cancer therapy with
EP1747284A4 (fr) Diagnostics et therapeutiques du cancer
EP1814544A4 (fr) Traitements anti-cancereux
EP1814909A4 (fr) Utilisation de aimp2dx2 pour diagnostiquer et traiter un cancer
EP1749095A4 (fr) Nouveaux cibles therapeutiques dans le cancer
HK1136822A1 (en) Therapeutic compounds and their use in cancer
PL1720611T3 (pl) Marker diagnostyczny dla raka
EP1797903A4 (fr) Agent de diagnostic pour tumeur
EP1874800A4 (fr) Agents diagnostiques et thérapeutiques
EP1841467A4 (fr) Therapie du cancer de combinaison avec des anticorps diriges contre l&#39;antigene membranaire specifique de la prostate
GB0418328D0 (en) Cancer methods and medicaments
EP1756166A4 (fr) Diagnostic et traitement du cancer de la prostate
EP1830847A4 (fr) Traitement anticancereux
EP1781685A4 (fr) Agents therapeutiques et diagnostiques
HK1110224A1 (en) Therapeutic agent for cancer
EP1871166A4 (fr) Vaccins contre le cancer et methodes therapeutiques
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428187D0 (en) Cancer treatment
EP1778873A4 (fr) Nouvelles cibles thérapeutiques contre le cancer
GB0326578D0 (en) Cancer diagnosis and therapy
EP1951914A4 (fr) Méthodes et agents diagnostiques et thérapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060904

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120206

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20120131BHEP

Ipc: A01N 37/18 20060101AFI20120131BHEP

17Q First examination report despatched

Effective date: 20120730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160112